Medicus Pharma Ltd. Common Stock (MDCX)
Healthcare
Drug Manufacturers - General
0.28 $
+4.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Medicus Pharma Ltd. Common Stock (MDCX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 88.8% of the shares are freely tradable; institutional investors hold 4.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
4.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
13.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
88.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
3.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
57Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Interchange Capital Partners, LLC | 2.93 | 1,661,871 | +4.7 | 03/31/2026 |
| Private Advisor Group, LLC | 0.42 | 240,055 | +36.8 | 03/31/2026 |
| Virtu Financial LLC | 0.13 | 74,045 | +0.0 | 03/31/2026 |
| Bryn Mawr Trust Company | 0.09 | 51,244 | +0.0 | 03/31/2026 |
| May Hill Capital, LLC | 0.09 | 50,622 | +42.1 | 03/31/2026 |
| Commonwealth Equity Services Inc | 0.09 | 48,143 | +69.0 | 03/31/2026 |
| UBS Group AG | 0.07 | 40,441 | +205.7 | 03/31/2026 |
| BlackRock Inc | 0.07 | 37,294 | +8.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Abante Quant Value FI | 0.13 | 74,248 | +0.0 | 03/31/2026 |
| iShares Micro-Cap ETF | 0.06 | 34,557 | +0.0 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.